Literature DB >> 8047624

Circadian pattern of motor activity in major depressed patients undergoing antidepressant therapy: relationship between actigraphic measures and clinical course.

N Raoux1, O Benoit, N Dantchev, P Denise, B Franc, J F Allilaire, D Widlöcher.   

Abstract

The 24-hour motor activity pattern was evaluated in 26 inpatients with major depression at treatment onset and after 4 weeks of antidepressant therapy. Clinical state, depression, and psychomotor retardation, as well as motor activity level and circadian rhythm, were simultaneously assessed. Treatment responders and nonresponders were also considered. Diurnal hypoactivity and reduced 24-hour rhythm amplitude were found at treatment onset. Activity level increased significantly on discharge. The rest-activity cycle for each depressed patient fit a cosine function of 24-hour periodicity. Data tended to show no phase shift but a large intragroup phase variability. Preliminary findings of a negative correlation between basic activity level and clinical improvement, and a trend toward responders having a lower activity level than nonresponders, suggest that activity could be used to predict therapeutic response.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8047624     DOI: 10.1016/0165-1781(94)90122-8

Source DB:  PubMed          Journal:  Psychiatry Res        ISSN: 0165-1781            Impact factor:   3.222


  21 in total

Review 1.  Psychomotor retardation in depression: biological underpinnings, measurement, and treatment.

Authors:  Jeylan S Buyukdura; Shawn M McClintock; Paul E Croarkin
Journal:  Prog Neuropsychopharmacol Biol Psychiatry       Date:  2010-10-31       Impact factor: 5.067

Review 2.  Opportunities for clinical applications of rest-activity rhythms in detecting and preventing mood disorders.

Authors:  Stephen F Smagula
Journal:  Curr Opin Psychiatry       Date:  2016-11       Impact factor: 4.741

3.  Rest-activity rhythm and sleep characteristics associated with depression symptom severity in strained dementia caregivers.

Authors:  Stephen F Smagula; Robert T Krafty; Briana J Taylor; Lynn M Martire; Richard Schulz; Martica H Hall
Journal:  J Sleep Res       Date:  2017-05-10       Impact factor: 3.981

4.  Motor-Activity Markers of Circadian Timekeeping Are Related to Ketamine's Rapid Antidepressant Properties.

Authors:  Wallace C Duncan; Elizabeth Slonena; Nadia S Hejazi; Nancy Brutsche; Kevin C Yu; Lawrence Park; Elizabeth D Ballard; Carlos A Zarate
Journal:  Biol Psychiatry       Date:  2017-03-28       Impact factor: 13.382

5.  Actigraphic registration of motor activity reveals a more structured behavioural pattern in schizophrenia than in major depression.

Authors:  Jan O Berle; Erik R Hauge; Ketil J Oedegaard; Fred Holsten; Ole B Fasmer
Journal:  BMC Res Notes       Date:  2010-05-27

Review 6.  Bringing the bedside to the bench, and then to the community: a prospectus for intervention research in late-life anxiety disorders.

Authors:  Eric J Lenze; Julie Loebach Wetherell
Journal:  Int J Geriatr Psychiatry       Date:  2009-01       Impact factor: 3.485

7.  Actigraphic measurement of the effects of single-dose haloperidol and olanzapine on spontaneous motor activity in normal subjects.

Authors:  Michael Kiang; Z Jeff Daskalakis; Bruce K Christensen; Gary Remington; Shitij Kapur
Journal:  J Psychiatry Neurosci       Date:  2003-07       Impact factor: 6.186

8.  Objective assessment of psychomotor retardation in primary care patients with depression.

Authors:  Grant L Iverson
Journal:  J Behav Med       Date:  2004-02

9.  Light at night during development in mice has modest effects on adulthood behavior and neuroimmune activation.

Authors:  Ruizhuo Chen; Aidan S Weitzner; Lara A McKennon; Laura K Fonken
Journal:  Behav Brain Res       Date:  2021-02-09       Impact factor: 3.332

Review 10.  Current Advances in Wearable Devices and Their Sensors in Patients With Depression.

Authors:  Seunggyu Lee; Hyewon Kim; Mi Jin Park; Hong Jin Jeon
Journal:  Front Psychiatry       Date:  2021-06-17       Impact factor: 4.157

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.